Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Adamas Pharma launches late-stage study of GOCOVRI in MS; shares up 4%

Published 04/03/2018, 12:40 PM
Updated 04/03/2018, 12:40 PM
© Reuters.  Adamas Pharma launches late-stage study of GOCOVRI in MS; shares up 4%
  • Enrollment is underway in a Phase 3 clinical trial assessing Adamas Pharmaceuticals' (ADMS +4.2%) GOCOVRI (amantadine) extended-release capsules in multiple sclerosis (MS) patients with walking impairment.
  • The primary endpoint of the 540-subject study is timed 25 foot walk (T25FW) compared to placebo. Two once-daily doses (137 mg and 274 mg) will be evaluated. According to ClinicalTrials.gov, the estimated completion date is September 2019.
  • The FDA approved GOCOVRI in August 2017 for dyskinesia (uncontrolled movements) in Parkinson's disease patients receiving levodopa-based therapy.
  • Previously: FDA OKs Adamas Pharma's amantadine for PD-related dyskinesia; shares up 35% after hours (Aug. 24, 2017)
  • Now read: Is Osmotica's Drug A Major Threat To Adamas's Gocovri?


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.